August 2023 Content Release Copied

08/31/20232023 ContentContent releasePhysician, Clinical, Admin, Billing

Problem & Codes Summary

Additions

New items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes may display to present surrounding nodes. Please see table below for a complete summary of changes.

Problem ICD-10 Codes
Chronic kidney disease stage 3A (disorder) N18.31 Chronic kidney disease, stage 3a
Chronic kidney disease stage 3B (disorder) N18.32 Chronic kidney disease, stage 3b
Systemic mastocytosis D47.02 Systemic mastocytosis

Lab Analytes & Panels

Additions

  • 10-hydroxycarbazepine, urine, ng/mL
  • 7-aminoclonazepam, urine, ng/mL
  • Adalimumab drug + antibody panel
  • Adalimumab drug level
  • Alpha-gal (O215), IgE
  • Alpha-Gal IgE panel
  • Alpha-hydroxyalprazolam, urine, ng/mL
  • Alpha-hydroxymidazolam, urine, ng/mL
  • Alprazolam, urine, ng/mL
  • Amitriptyline, urine
  • Anti-adalimumab antibody
  • Anti-HNA antibodies
  • BIRC3 variant
  • Brivaracetam, urine, ng/mL
  • BTK variant
  • Bupropion, urine, ng/mL
  • Carbamazepine-10,11 epoxide urine, ng/mL
  • Carbamazepine, urine, ng/mL
  • CARD11 variant
  • CD79A variant
  • CD79B variant
  • Chlordiazepoxide, urine, ng/mL
  • Citalopram, urine, ng/mL
  • Class description
  • Clobazam, urine, ng/mL
  • Clomipramine, urine, ng/mL
  • Clonazepam, urine, ng/mL
  • Desipramine, urine, ng/mL
  • Desmethyldoxepin, urine, ng/mL
  • Doxepin, urine, ng/mL
  • Drug profile, anticonvulsants panel, urine
  • Drug profile, antidepressants panel, urine
  • Drug profile, benzodiazepines, urine
  • Duloxetine, urine, ng/mL
  • Ethanol, urine, quant, mg/dL
  • Felbamate, urine, ng/mL
  • Fluoxetine, urine, ng/mL
  • Gabapentin, urine, ng/mL
  • Heinz body stain, induced, result
  • Herpes simplex virus 1 and 2 (IgG), with reflex to HSV-2 inhibition
  • Herpes simplex virus 1 and 2 (IgG), with reflex to HSV-2 inhibition panel
  • Hydroxybupropion, urine, ng/mL
  • Imipramine, urine, ng/mL
  • Lacosamide, urine, ng/mL
  • Lamb (F88), IgE
  • Lamotrigine, urine, ng/mL
  • Levetiracetam, urine, ng/mL
  • Lorazepam, urine, ng/mL
  • Midazolam, urine, ng/mL
  • Mirtazapine, urine, ng/mL
  • MYD88 variant
  • N-desmethylcitalopram, urine, ng/mL
  • N-desmethyltrimipramine, urine, ng/mL
  • Naveris NavDx panel
  • Naveris NavDx result
  • Nordiazepam, urine, ng/mL
  • Norfluoxetine, urine, ng/mL
  • Nortriptyline, urine, ng/mL
  • O-desmethylvenlafaxine, urine, ng/mL
  • Oxazepam, urine, ng/mL
  • Paroxetine, urine, ng/mL
  • PLCG2 variant
  • Pregabalin, urine, ng/mL
  • Primidone, urine, ng/mL
  • Protriptyline, urine, ng/mL

Medications

Additions

  • ALLO-501A invest IV
  • BGB-A425 invest IV
  • BL-B01D1 invest IV
  • Camonsertib invest Oral
  • DK2^10 invest Subcutaneous
  • GDC-6036 invest Oral
  • GSK4428859A invest IV
  • HF158K1 invest IV
  • HST-1011 invest Oral

Updates

  • Rufinamide, urine, ng/mL
  • Sertraline, urine, ng/mL
  • Temazepam, urine, ng/mL
  • Tempus xR addendum panel
  • Tempus xR MMR panel
  • Tempus xR panel
  • Tempus xR RNA seq panel
  • Tiagabine, urine, ng/mL
  • Topiramate, urine, ng/mL
  • Trimipramine, urine, ng/mL
  • Varicella zoster virus DNA, RT-PCR, quant, Log Copies/mL
  • Venlafaxine, urine, ng/mL
  • Zolpidem, urine, ng/mL
  • Zonisamide, urine, ng/mL
  • Ianalumab (VAY736) invest IV
  • ICT01 invest IV
  • IMT-009 invest IV
  • INCB099280 invest Oral
  • LBL-007 invest IV
  • LCB84 invest IV
  • Palmitoylethanolamide invest Oral
  • TAK-186 invest IV
  • Tiragolumab-Atezolizumab invest IV
Medication Update
ABBV-101 invest IV New form available: 10 mg tablet
ART0380 invest Oral New form available: 200 mg tablet
CUE-101 invest IV New forms available:

  • 50 mg vial (10 mg/mL) solution
  • 90 mg vial (10 mg/mL) solution
Leuprolide Subcutaneous (6 month) New maximum single dose (flat):

  • 4 5 mg

New quick sigs available:

  • Leuprolide 0 mg subcutaneously As Directed
  • Leuprolide 0 mg subcutaneously once
  • Leuprolide 0 mg subcutaneously once; NOTE: This product is equivalent to Camcevi.
  • Leuprolide 0 mg subcutaneously once; NOTE: This product is equivalent to Eligard.
  • Leuprolide 0 mg subcutaneously once; NOTE: This product is equivalent to Fensolvi.
Methylprednisolone IV New unit available: mg/m2
NUC-3373 invest IV New form available:

  • 125 mg/mL solution

Discontinued form:

  • 10 mL solution
SKB264 invest IV New form available: 200 mg recon soln

Regimen Library

Additions

Granulocyte colony-stimulating factor (G-CSF)

Udenyca (Pegfilgrastim-cbqv Subcutaneous Auto-Injector) has been added to regimens containing prechecked pegfilgrastim.

The following new regimens have been added into the regimen library.

Regimen Name Diagnosis
Anastrozole + Leuprolide Q3M (5 years) Breast Cancer
Avapritinib Q30D (Indolent Systemic Mastocytosis) Systemic Mastocytosis
Exemestane + Leuprolide Q3M (5 years) Breast Cancer
Irinotecan + Cetuximab D1,8 Q14D Colon Cancer, Rectal Cancer
Lenalidomide D1-28 + Rituximab IV C1,3,5,7,9,11 Q28D (Part 2 of 2: Frontline FL Maintenance) Lymphoma, Non-Hodgkin (NHL) (Parent)
Lenalidomide D2-22 + Rituximab IV D1,8,15,22 fb D1 Q28D (Part 1 of 2: Frontline FL Induction) Lymphoma, Non-Hodgkin (NHL) (Parent)
Letrozole + Leuprolide Q3M (5 years) Breast Cancer
Olaparib + Abiraterone + Prednisone + Goserelin Q28D Prostate Cancer
Olaparib + Abiraterone + Prednisone + Leuprolide Q28D Prostate Cancer
Paclitaxel + Carboplatin + Cetuximab D1,8,15 Q21D Head and Neck Cancer (Parent)
Pembrolizumab (Dose Banding) + Pemetrexed Maintenance Q42D Lung Cancer, Non-small Cell (NSCLC)
Quizartinib (Maintenance) Q28D Leukemia, Acute Myeloid (AML)
Rituximab IV D1,8,15,22 + High-Dose Methylprednisolone D1-3 Q28D Leukemia, Chronic Lymphocytic (CLL), Lymphoma, Non-Hodgkin (NHL) (Parent)
Rozanolixizumab-noli (Rystiggo) Q7D Myasthenia Gravis
Tamoxifen + Leuprolide Q3M (5 years) Breast Cancer

Updates

Antiemetic Prophylaxis

To improve ease of ordering antiemetic prophylaxis, over the next two months, a prechecked prescription order for oral ondansetron will be included in all regimens containing a moderate to high emetic risk oral oncolytic agent, per NCCN Guidelines. As an exception, oral oncolytic agents with risk for QT prolongation and therefore potential additive toxicity with ondansetron, will not have ondansetron prechecked.

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

  • All Problems
  • Arthritis, Rheumatoid
  • Brain Tumor (Parent)
  • Breast Cancer
  • Cancer of Unknown Primary
  • Fallopian Tube Cancer
  • Gastrointestinal Stromal Tumor (Parent)
  • Hepatocellular Carcinoma (HCC)
  • Leukemia, Acute Myeloid (AML)
  • Leukemia, Chronic Myeloid (CML)
  • Lung Cancer, Non-small Cell (NSCLC)
  • Lung Cancer, Small Cell (SCLC)
  • Lymphoma, Non-Hodgkin (NHL) (Parent)
  • Melanoma, Skin
  • Multiple Myeloma (MM)
  • Myelofibrosis
  • Myeloproliferative Disorder
  • Neuroendocrine Tumor, Carcinoid (Parent)
  • Ovarian and Primary Peritoneal Cancer
  • Pancreatic Cancer
  • Polycythemia Vera
  • Prostate Cancer
  • Renal Cell Carcinoma (RCC)
  • Thyroid Cancer (Parent)
  • Uterine Cancer (Parent)
  • Waldenstrom’s Macroglobulinemia

Renames

Previous Name New Name
Avapritinib Q30D (Systemic Mastocytosis) Avapritinib Q30D (Advanced Systemic Mastocytosis)

Research

Updates

Updated Reference Information Updated Drug Service Order Information Updated Regimen Instruction Other Changes
USOR 18263 X
USOR 20186 X X Now available:

  • USOR 20186 Cohort L GDC-6036 (PO; Daily) Q21D
  • USOR 20186 Cohort M Camonsertib D1-3, D8-10 Q21D USOR 20186 Cohort N Camonsertib D1-3, D8-10 Q21D

No longer available:

  • USOR 20186 Cohort D Atezolizumab Q21D
  • USOR 20186 Cohort F Trastuzumab Emtansine Q21D USOR 20186 Cohort H GDC-0077 (PO; Daily) Q28D
  • USOR 20186 Cohort I Belvarafenib (PO; BID) Q28D
USOR 20398 X
USOR 21225 X
USOR 21271 No longer available:

  • USOR 21271 Zn-c3 (PO; Daily) Q21D

Now available:

  • USOR 21271 ZN-c3 (5:2 intermittent) Q21D
USOR 21455 X X
USOR 21459 X
USOR 22002 X
USOR 22047 X
USOR 22073 X X X
USOR 22101 X X X
USOR 22147 X X X
USOR 22151 X
USOR 22166 X X X
USOR 22169 X X X
USOR 22181 X X X
USOR 22249 X X
USOR 22252 X X
USOR 22329 X

Billing & HCPCS Codes

Updates

Medication HCPCS Codes
Adalimumab-adbm Subcutaneous J3590 per 40 mg
Adalimumab-bwwd Subcutaneous J3590 per 40 mg
Dexamethasone Sodium Phosphate (perineural) J1100 per 1 mg
Docetaxel Intravesical J9171 per 1 mg
Efgartigimod-hyaluronidas-qvfc (Vyvgart Hytrulo) J3590 per 5.6 mL
Lecanemab-irmb (Leqembi) J0174 per 1 mg
RSVPreF3 Antigen-AS01E (PF) IM 90679 per 0.5 mL
RSVPreF3 Antigen (Component Vial 2 of 2) 90679 per 0.5 mL
RSV Vaccine, PreF A and PreF B (PF) IM J3590 per 0.5 mL
Valoctocogene roxaparvovc-rvox J3590 per 0.6 x 10e14 vg